About
Overview
Leadership
Area of Focus
Congestion in Heart Failure
Outpatient Parenteral Antimicrobial Treatment (OPAT)
Research and Development
FUROSCIX
®
(furosemide injection) for subcutaneous administration
scCeftriaxone
Clinical Development & Medical Affairs
Investor Relations
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Corporate Governance
Governance Highlights
Committee Composition
Financial Information
Sec Filings
News & Events
News Releases
Event Calendar
Presentations
Investor Resources
Investor FAQ
Information Request
E-mail Alerts
Ir Contacts
Media Resources
Careers
Contact Us
Legal
Privacy Policy
Terms of Use
scPharmaceuticals
Areas of Focus
Research & Development
Careers
Recent News
March 23, 2021
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Read More
February 25, 2021
scPharmaceuticals to Present in Two Upcoming Investor Conferences
Read More
February 23, 2021
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX
®
NDA
Read More
February 17, 2021
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
Read More
All News
